Third Lawsuit Is Filed Against HRSA for Blocking the Rebate Model
11/19/2024 – Third Lawsuit Is Filed Against HRSA for Blocking the Rebate Model On November 14, 2024, Eli Lilly and Company (Lilly) filed a lawsuit against HHS and HRSA in…
J&J Sues HHS and HRSA Over HRSA’s Opposition to J&J’s Proposed Rebate Model
11/14/2024 – J&J Sues HHS and HRSA Over HRSA’s Opposition to J&J’s Proposed Rebate Model On November 12, 2024, Johnson and Johnson Health Care System Inc. (J&J) filed a lawsuit…
Boehringer Ingelheim Will Require Claims Data Submission for Single Contract Pharmacy
11/5/2024 – Beginning December 2, 2024, Boehringer Ingelheim Pharmaceuticals, Inc. (BI) will require covered entities to submit 340B claims data to 340B ESP™ for a single contract pharmacy. This policy applies…
VP of Pharmacy for Positive Impact Health Centers Emily Blaiklock on 340B Generic Drug Program for Rural/Ryan White Clinics WOYM 10-4
VP of Pharmacy for Positive Impact Health Centers Emily Blaiklock on 340B Generic Drug Program for Rural/Ryan White Clinics WOYM 10-4, listen to the interview here: https://wlds.com/audio/vp-of-pharmacy-for-positive-impact-health-centers-emily-blaiklock-on-340b-generic-drug-program-for-rural-ryan-white-clinics-woym-10-4/
J&J Will No Longer Offer Up-Front 340B Discounts to DSH CEs for Stelara and Xarelto; Drugmaker Unilaterally Imposing Rebate Model
Johnson & Johnson Health Care System Inc. (J&J) announced last week that, effective October 15, 2024, disproportionate share hospital (DSH) covered entities will no longer have access to up-front 340B…
Medicare to Cover PrEP and Associated Services Under Part B Only
CMS announced that it expects to release a final National Coverage Determination (NCD) late next month that will move the PrEP coverage benefit from Medicare Part D to Medicare Part…
Alkermes and Viatris Impose 340B Program Contract Pharmacy Restrictions
Alkermes and Viatris have become the 36th and 37th manufacturers, respectively, to impose restrictions on contract pharmacy arrangements. These restrictions are effective July 22 and August 1, respectively, but please…
RWC-340B Sends Letter of Support in Whistleblower Suit Alleging Manufacturer Overcharges
On January 24, 2024, RWC-340B sent a letter of support in connection with a False Claims Act case that, if successful, could clear a pathway for Ryan White clinics (RWCs)…
CMS Defers Decision on Part D 340B Modifier Proposal
CMS published revised guidance on December 14, 2023 to defer its decision to require 340B point-of-sale modifiers for Part D drugs beginning in 2026. RWC-340B submitted comments to CMS’s initial proposal…
RWC-340B Submits Comments to Federal Trade Commission
As you may know, the Federal Trade Commission recently requested public comments on the impacts of Pharmacy Benefit Managers’ practices, affecting drug affordability and access. Today, RWC-340B submitted detailed…